Clene Secures New Debt for Strategic Growth
Clene Inc. has made a substantial move to enhance its financial stability by securing a new debt facility worth $10 million. This newly acquired funding replaces $7.85 million of its previous debt from Avenue Capital, thus improving Clene's cash position significantly. With this financial boost, Clene aims to accelerate the data generation necessary for its CNM-Au8 therapy, which is aimed at combating amyotrophic lateral sclerosis (ALS) through an expedited regulatory process.
Details of the New Debt Facility
The new secured, partially convertible debt facility is expected to close soon. It carries a 12% annual interest rate and has a maturity period of 18 months. For the first year, Clene will only need to pay interest, providing them ample time to utilize the funds effectively. Notably, 65% of this debt is convertible into Clene's common stock at a fixed conversion price of $5.67, which reflects a remarkable 130% premium compared to the company's stock price when the agreement was reached.
Previous Financing and Strategic Implications
In May 2021, Clene had entered into a significant loan agreement with Avenue. Over that time, Clene had borrowed $20 million, and as of recently, approximately $7 million remains outstanding. The company plans to use the fresh funds predominantly to support clinical studies, particularly focusing on the data requirements set forth by the U.S. Food and Drug Administration. This strategic financing will facilitate the completion of their clinical program for CNM-Au8, enhancing its chances for approval.
Comments from Leadership
Rob Etherington, President and CEO of Clene, expressed gratitude towards the longstanding trust of their investors. Etherington noted the critical role of this new financing in extending Clene’s cash runway. The intention is to support further data collection that could solidify CNM-Au8's position in the competitive therapeutic landscape of ALS. By securing this funding, Clene is set to generate the necessary additional data to pave the way for potential approval of CNM-Au8 via an accelerated pathway.
About Clene Inc.
Clene Inc. operates as a late clinical-stage biopharmaceutical company. It specializes in developing innovative therapies targeting neurodegenerative diseases, including ALS and multiple sclerosis. The flagship product, CNM-Au8, showcases a promising approach to enhancing neuronal health through improving mitochondrial functions and countering oxidative stress.
Innovative Therapy: CNM-Au8
CNM-Au8 is a unique oral suspension of gold nanocrystals specifically designed to restore neuronal health and function. It enhances energy production within the nervous system, which may lead to neuroprotection and the restoration of myelin, a critical factor in brain function. This innovative therapy stands out as Clene's key offering in the fight against neurodegenerative disorders.
Frequently Asked Questions
What recent financing did Clene Inc. secure?
Clene Inc. has secured a new debt facility worth $10 million to improve its cash position.
How will Clene use the funds from the new debt facility?
The funds will primarily support data generation for the CNM-Au8 drug application aimed at ALS treatment.
What is the interest rate on the new debt facility?
The new debt facility carries a fixed interest rate of 12% per annum.
What can you tell me about CNM-Au8?
CNM-Au8 is an investigational therapy designed to improve neuronal health by enhancing energy production and reducing oxidative stress.
Who is leading Clene Inc.?
Rob Etherington serves as the President and CEO of Clene Inc., guiding the company’s strategic initiatives.
